Polycythemia
Mostrando 1-12 de 115 artigos, teses e dissertações.
-
1. Outcome of patient with Polycythemia Rubra Vera and psychiatric symptoms
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese
ABSTRACT Introduction: Constitutional symptoms and thrombohemorrhagic events are common in patients with myeloproliferative neoplasms (MPNs). Hence, the treatment’s primary goal is to control symptoms and improve the quality of life (QoL). In order to assess response to therapy, symptom burden, and QoL among patients with MPN, the “Myeloproliferative Ne
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
3. Erythropoietin-producing clear cell renal cell carcinoma associated with secondary polycythemia
ABSTRACT Background Carica papaya Linn. has high nutraceutical and pharmacological values. The leaves possess antimicrobial, anti-tumor and antioxidant properties. They are used to treat thrombocytopenia during dengue fever and the leaf extract is commercially available as tablets under the name Caripill™ (MicroLabs, Bengaluru). Nevertheless, platelet tra
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06
-
4. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
ABSTRACT Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
5. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
ABSTRACT Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis,
Hematol., Transfus. Cell Ther.. Publicado em: 2018-06
-
6. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
ABSTRACTMyeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgr
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-10
-
7. Thyroid function, autoimmunity and nodules in hematological malignancies
Objective Hematological malignancies encompass a large spectrum of disease entities whose treatment by chemo/radiotherapy could lead to thyroid complications. To the best of our knowledge, no study has simultaneously addressed thyroid function, autoimmunity and nodularity. Therefore, we decided to conduct one.Materials and methods We evaluated 82 Caucasian p
Arch. Endocrinol. Metab.. Publicado em: 2015-06
-
8. Expressão de microRNAs em leucócitos e células CD34+ em Policitemia Vera / microRNA expression in leukocytes and CD34+ cells in Polycythemia Vera
A Neoplasia Mieloproliferativa Crônica (NMPC)- Politemia Vera é uma desordem clonal caracterizada pelo acúmulo de eritrócitos, leucócitos, plaquetas e progenitores normais na ausência de um estímulo definido. Apesar dos avanços no diagnóstico de PV e da descrição de mecanismos envolvidos no estabelecimento da doença sua patogênese permanece desc
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 25/01/2012
-
9. Philadelphia-negative chronic myeloproliferative neoplasms
Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2012
-
10. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon 12 and MPL W515K/L, besides chromosomal abnormalities. Furthermore, molecular and cytogenetic alterations
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
11. The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
12. Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients
A desregulação da apoptose parece participar da fisiopatologia da policitemia vera (PV). Este estudo avaliou a expressão das moléculas da família Bcl-2 em células hematopoéticas CD34 + e leucócitos de 12 pacientes com PV. Foram realizados: a quantificação da expressão gênica por PCR em tempo real utilizando kit Sybrgreen Quantitect, avaliação d
Brazilian Journal of Pharmaceutical Sciences. Publicado em: 2011-12